Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation

Ifigeneia Tzannou, Swati Naik, Kathryn Leung, +18

Journal of Clinical Oncology

Bk VirusCell TherapyTransplantationEpstein-barr VirusStem Cell Transplantation +13

Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant

Premal Lulla, Swati Naik, Spyridoula Vasileiou, +21

Blood

T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects

Spyridoula Vasileiou, Premal Lulla, Ifigeneia Tzannou, +19

Journal of Clinical Oncology

“Mini” bank of only 8 donors supplies CMV-directed T cells to diverse recipients

Ifigeneia Tzannou, Ayumi Watanabe, Swati Naik, +11

Blood Advances

Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections

Spyridoula Vasileiou, Anne M. Turney, Manik Kuvalekar, +8

Haematologica

Respiratory Virus ImmunityVirus EpidemiologyRespiratory Viral InfectionsViral PathogenesisImmunology +20

The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma

Premal Lulla, Ifigeneia Tzannou, Spyridoula Vasileiou, +21

Science Translational Medicine

Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer

Valentina Hoyos, Spyridoula Vasileiou, Manik Kuvalekar, +22

Therapeutic Advances in Medical Oncology

Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL

Swati Naik, Spyridoula Vasileiou, Ifigeneia Tzannou, +21

Blood

Characterizing the Cellular Immune Response to Parainfluenza Virus 3

Paibel Aguayo‐Hiraldo, Reuben J. Arasaratnam, Ifigeneia Tzannou, +7

The Journal of Infectious Diseases

Host ResponseBk VirusVirus-specific T CellsImmunologyAntiviral Response +11

Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients

Spyridoula Vasileiou, LaQuisa Hill, Manik Kuvalekar, +15

Haematologica

ImmunologyImmunodominanceProfoundly ImmuneCovid-19 EpidemiologyImmunotherapy +16